319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC
J.C-H. Yang, G. Liu, S. Lu, J. He, M. Burotto, Sarah Mathilda Vincent, J. Yin, X. Ma, S. Popat
Topics & Concepts
CrizotinibAlectinibMedicineRefractory (planetary science)Randomized controlled trialInternal medicineOncologyLung cancerPhysicsMalignant pleural effusionAstrobiologyLung Cancer Treatments and MutationsGastrointestinal Tumor Research and TreatmentChronic Lymphocytic Leukemia Research